Boosting Osimertinib Blood Brain Barrier Penetration

Inclusion criteria

• ✓. The patient has metastatic EGFR-mutated NSCLC and is treated with osimertinib as part of regular care with CT-confirmed stable disease or better. Patients with (signs of) disease progression, are also eligible if their treating physician deems the treatment to be appropriate beyond progression and the expected osimertinib treatment duration is at least 1 month.
• ✓. The patient has an European Cooperative Oncology Group (ECOG) performance status (PS) of 0-2.
• ✓. The patient is 18 years of age or older.
• ✓. The patient is able and willing to sign informed consent prior to any tests or procedures.
• ✓. The patient is able and willing to undergo additional blood sampling for e.g. therapeutic drug monitoring.
• ✓. The patient is able and willing to undergo lumbar punctions to obtain CSF.
• ✓. The patient must meet the criteria stated in the approved regulatory indication(s) for osimertinib where the clinical study will be performed and agree to the restrictions, monitoring, and dose-adjustment criteria stipulated in the associated product label.
• ✓. The patient does not harbour the ABCG2 34G\>A single nucleotide polymorphism.

Exclusion criteria